A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

Endometrial Neoplasms Clinical Trial

Official title:

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02725268
• Other study ID #: C31004
• Secondary ID: U1111-1168-18242
• Status: Completed
• Phase: Phase 2
• Start date: April 1, 2016
• Est. completion date: October 30, 2020

Study information

• Verified date: October 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Description:

The drugs being evaluated in this study are sapanisertib and MLN1117. Sapanisertib is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination.

The study will enroll approximately 241 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of 4 treatment groups:

• Paclitaxel 80 mg/m^2

• Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg

• Sapanisertib 30 mg

• Sapanisertib 4 mg + MLN1117 200 mg

Participants will receive either paclitaxel intravenous (IV) weekly, Paclitaxel IV along with sapanisertib orally, sapanisertib orally, or sapanisertib and MLN1117 orally.

This is a multicenter, multinational trial. Participants will make multiple visits to the clinic, with an end of treatment visit (EOT) which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for PFS and overall survival (OS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 241
• Est. completion date: October 30, 2020
• Est. primary completion date: July 2, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologic or cytologic diagnosis of endometrial carcinoma (including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma).

2. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy or established treatments.

3. At least 1 prior platinum-based chemotherapeutic regimen, but not more than 2 prior chemotherapeutic regimens, for management of endometrial carcinoma. Prior treatment may include chemotherapy, chemotherapy/radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radio-sensitized therapy will be considered a systemic chemotherapy regimen.

4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded). Each lesion must be greater than or equal to (>=) 10 millimeter (mm) in long axis when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam. Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.

5. Tumor accessible and participant consents to undergo fresh tumor biopsies.

6. Female participants 18 years or older.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

8. Female participants who:

• Are postmenopausal for at least 1 year before the screening visit, OR

• Are surgically sterile, OR

• If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc.]) after the last dose of study drug, OR

• Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)

9. Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:

• Bone marrow reserve consistent with absolute neutrophil count (ANC) >= 1500 per micro liter (/mcL); platelet count >= 100,000/mcL; hemoglobin A1c (HbA1c) less than (<) 6.5 percent (%).

• Total bilirubin must be less than or equal to (<=) 1.5 * the upper limit of normal (ULN).

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be <= 2.5
• the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease in liver.

• Creatinine clearance >= 50 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) based either on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection.

• Fasting serum glucose < 130 milligram per deciliter (mg/dL) and fasting triglycerides <= 300 mg/dL.

10. Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and suitable venous access for the study-required blood sampling.

11. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion Criteria:

1. Positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug. Women who are lactating and breastfeeding are not eligible.

2. Previous treatment with any weekly taxane regimen.

3. History of severe hypersensitivity reactions to paclitaxel or any of its excipients.

4. Previous treatment with phosphoinositide 3-kinase (PI3K), serine/threonine-specific protein kinase (AKT), dual PI3K/ mammalian (or mechanistic) target of rapamycin (mTOR) inhibitors, target of rapamycin complex 1/2 (TORC1/2) inhibitors or TORC1 inhibitors.

5. Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (participants already receiving erythropoietin on a chronic basis for >=4 weeks are eligible).

6. Participants who are taking proton pump inhibitors (PPIs) within 7 days of the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H2 receptor antagonists within 24 hours of the first dose of study drug.

7. A prothrombin time (PT) or activated partial thromboplastin time (aPTT) above the ULN or a history of a coagulopathy or bleeding disorder.

8. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.

9. Sensory or motor neuropathy >= Grade 2.

10. Central nervous system (CNS) metastasis, endometrial leiomyosarcoma, or endometrial stromal sarcoma.

11. Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of sapanisertib or MLN1117. In addition, participants with enteric stomata are also excluded.

12. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active infection, or any other condition that could compromise participation of the participant in the study.

13. Known human immunodeficiency virus infection.

14. History of any of the following within the last 6 months before administration of the first dose of study drug:

• Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures.

• Ischemic cerebrovascular event, including transient ischemic attack and artery revascularization procedures.

• Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).

• Placement of a pacemaker for control of rhythm.

• New York Heart Association Class III or IV heart failure.

• Pulmonary embolism.

15. Significant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including:

• Uncontrolled hypertension (that is, either systolic blood pressure > 180 millimeter of mercury [mm Hg] or diastolic blood pressure > 95 mm Hg).

• Pulmonary hypertension.

• Uncontrolled asthma or oxygen saturation < 90% by arterial blood gas analysis or pulse oximetry on room air.

• Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement.

• Medically significant (symptomatic) bradycardia.

• History of arrhythmia requiring an implantable cardiac defibrillator.

• Baseline prolongation of the rate-corrected QT interval (QTc; example, repeated demonstration of QTc interval > 480 millisecond [ms], or history of congenital long QT syndrome, or torsades de pointes).

16. Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

17. Participants with endometrioid histology and histologically confirmed expression of estrogen receptors (ER) and/or progesterone receptors (PgR) who have not received prior endocrine therapy and for whom endocrine therapy is currently indicated.

Related Conditions & MeSH terms

• Endometrial Neoplasms

Intervention

Drug:
• Paclitaxel
Paclitaxel intravenous solution.
• Sapanisertib
Sapanisertib capsules.
• MLN1117
MLN1117 capsules.

Locations

Country	Name	City	State
Australia	Monash Medical Centre Clayton	Clayton	Victoria
Australia	Sunshine Hospital	Footscray	Victoria
Australia	Royal Brisbane and Women's Hospital	Herston	Queensland
Australia	St George Hospital	Kogarah	New South Wales
Australia	Cabrini Hospital Malvern	Malvern	Victoria
Australia	Peter MacCallum Cancer Centre-East Melbourne	Melbourne	Victoria
Australia	Westmead Hospital	Westmead	New South Wales
Belgium	Cliniques Universitaires Saint-Luc	Bruxelles
Belgium	UZ Antwerpen	Edegem	Antwerpen
Belgium	UZ Leuven	Leuven
Belgium	Centre Hospitalier Universitaire de Liege Site Sart Tilman	Liege
Belgium	GasthuisZusters Antwerpen Sint-Augustinus	Wilrijk
Canada	Tom Baker Cancer Centre	Calgary	Alberta
Canada	Juravinski Cancer Clinic	Hamilton	Ontario
Canada	LHSC - Victoria Hospital	London	Ontario
Canada	CHUM Hopital Notre-Dame	Montreal	Quebec
Canada	Ottawa Hospital Cancer Centre	Ottawa	Ontario
Canada	University Health Network - Princess Margaret Cancer Centre	Toronto	Ontario
Germany	Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum	Berlin
Germany	Universitaetsklinikum Carl Gustav Carus TU Dresden	Dresden	Sachsen
Germany	Universitaetsmedizin Greifswald	Greifswald	Mecklenburg Vorpommern
Germany	Medizinische Hochschule Hannover	Hannover	Niedersachsen
Germany	Universitaetsklinikum Schleswig-Holstein - Campus Luebeck	Luebeck	Schleswig Holstein
Italy	Spedali Civili di Brescia	Brescia
Italy	Ente Ospedaliero Ospedali Galliera	Genova
Italy	Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori	Meldola	Forli - Cesena
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano
Italy	IEO Istituto Europeo di Oncologia	Milano
Italy	Istituto Tumori Napoli Fondazione G. Pascale	Napoli
Italy	Azienda Unita Sanitaria Locale di Ravenna	Ravenna
Italy	Fondazione Policlinico Universitario Agostino Gemelli	Roma
Italy	Istituto Nationale Tumori Regina Elena	Roma
Italy	Universita degli Studi di Roma "La Sapienza" - Umberto I Policlinico di Roma	Roma
Netherlands	Academisch Medisch Centrum	Amsterdam	Noord-holland
Netherlands	Universitair Medisch Centrum Groningen	Groningen
Netherlands	Maastricht Universitair Medisch Centrum	Maastricht	Limburg
Netherlands	Erasmus Medisch Centrum Daniel den Hoed	Rotterdam	Zuid-holland
Netherlands	Universitair Medisch Centrum Utrecht	Utrecht
Norway	Haukeland universitetssykehus, Kvinneklinikken	Bergen
Norway	Radiumhospitalet	Oslo
Norway	Stavanger University Hospital	Stavanger
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Centro Integral Oncologico Clara Campal	Madrid
Spain	Hospital Universitario Clinico San Carlos	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramon y Cajal	Madrid
Spain	MD Anderson Cancer Centre	Madrid
Spain	Instituto Valenciano de Oncologia IVO	Valencia
United Kingdom	Bristol Haematology and Oncology Centre	Bristol	Avon
United Kingdom	University Hospital Coventry	Coventry
United Kingdom	Royal Devon and Exeter Hospital (Wonford)	Exeter	Devon
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Hammersmith Hospital	London	Greater London
United Kingdom	Royal Marsden Hospital	London	Greater London
United Kingdom	University College London Hospitals	London	Greater London
United Kingdom	The Christie	Manchester	Greater Manchester
United Kingdom	Royal Marsden Hospital	Sutton	Surrey
United States	Augusta University	Augusta	Georgia
United States	University of Alabama Comprehensive Cancer Center	Birmingham	Alabama
United States	Massachusetts General Hospital Cancer Center	Boston	Massachusetts
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Marin Cancer Care	Greenbrae	California
United States	Franciscan St. Francis Health	Indianapolis	Indiana
United States	University of California San Diego Medical Center	La Jolla	California
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	NYU Langone Medical Center Clinic	New York	New York
United States	Oklahoma University Health Sciences Center	Oklahoma City	Oklahoma
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	University of Arizona Cancer Center	Phoenix	Arizona
United States	University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital	Pittsburgh	Pennsylvania
United States	Washington University	Saint Louis	Missouri
United States	University of California at San Francisco (PARENT)	San Francisco	California
United States	Stanford School of Medicine	Stanford	California
United States	H. Lee Moffitt Cancer Center and Research Institute, Inc	Tampa	Florida
United States	Florida Cancer Specialists	West Palm Beach	Florida
United States	University of Kansas Medical Center Research Institute, Inc.	Westwood	Kansas

Sponsors (3)

Lead Sponsor	Collaborator
Millennium Pharmaceuticals, Inc.	European Network of Individualized Treatment in Endometrial Cancer - ENITEC, European Network of Translational Research in Ovarian Cancer - EUTROC

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Germany,  Italy,  Netherlands,  Norway,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	Up to approximately 30 months
Secondary	Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.	From the first dose of study drug through 30 days after the last dose of study drug (Up to approximately 54 months)
Secondary	Overall Survival (OS)	OS is defined as the time in months from the date of randomization to the date of death.	Up to approximately 54 months
Secondary	Time to Tumor Progression (TTP)	TTP is defined as the time in months from the date of randomization to the date of first documentation of progression. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	Up to 30 months
Secondary	Overall Response Rate (ORR)	ORR is defined as the percentage of participants who achieved a best response of a complete response (CR) or partial response (PR). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.	Up to 30 months
Secondary	Clinical Benefit Rate (CBR)	CBR is defined as the percentage of participants with CR or PR or SD (SD of any duration). Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	Up to 30 months
Secondary	Clinical Benefit Rate (CBR) at Week 16 (CBR-16)	CBR-16 is defined as the percentage of participants who achieved CR or PR of any duration or have SD with a duration of at least 16 weeks. Per RECIST v1.1, CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	Week 16